GONA
Gonadorelin
Synthetic gonadotropin-releasing hormone: the decapeptide pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2, identical in sequence to the hormone released by the hypothalamus. It binds the GnRH receptor on the anterior pituitary. Unlike most entries here it is not an analogue of anything — it is the natural sequence.
Gonadorelin has 14 registered human studies on ClinicalTrials.gov, reaching phase 4, covering 581 planned or enrolled participants across the 14 studies that published a figure. An FDA-approved product contains Gonadorelin — LUTREPULSE KIT (NDA019687). 110 papers naming it were published in the last ten years.
Collected 2026-08-02 from ClinicalTrials.gov and Drugs@FDA. Counts include only trials whose registered intervention names Gonadorelin; the registry search is fuzzy, so every match is re-checked. None of this says whether Gonadorelin works or is safe.
FDA status
Approved
Human studies
14
Furthest phase
Phase 4
Papers, 10 yr
110
Readership
681
monthly average, Feb–Jul 2026
Tracking since 2026-07-29 · About this data
What has actually been tested in humans
An approved product exists
14
Registered human studies
Phase 4
Furthest phase reached
581
Planned or enrolled participants, across 14 studies that published a figure
Approved
FDA-approved product — LUTREPULSE KIT
1,000 loose registry matches were checked and 14 confirmed — 986 named something else and were discarded. We count a study only when Gonadorelin is named as an intervention in it.
Registered means registered — not that the study finished, and not that it found anything. The grade is mechanical: it is computed from the registry and the FDA record alone, and it grades how much is known, never whether a compound is good or safe. Collected 2026-08-02 from ClinicalTrials.gov and Drugs@FDA. Check the query.
What Gonadorelin is, and what it has been studied for
Gonadorelin is classified by ChEMBL as a protein. Its FDA substance identifier is 9O7312W37G.
Across 14 registered trials, it has been studied in Obesity, Infertility, Sleep Restriction and Hypogonadotropic Hypogonadism. A condition here is what a sponsor registered the trial under — it records what was investigated, not what was shown.
The trials were run by University of Colorado, Denver and Nelly Pitteloud among others. A named commercial sponsor means a compound is in formal development; its absence does not mean the opposite, only that no company has registered a trial under its own name.
How far it got
Gonadorelin reached Phase 4 across 14 registered trials.
An FDA-approved product contains Gonadorelin. Approval covers a specific product for a specific use — it is not a verdict on the molecule.
Is anyone studying Gonadorelin?
Papers published each year that name Gonadorelin in the title or abstract, with the clinical trials that started in the same year marked beneath. Ten calendar years.
| Year | Publications | Trials started | Complete year |
|---|---|---|---|
| 2017 | 12 | 1 | Yes |
| 2018 | 6 | 0 | Yes |
| 2019 | 14 | 2 | Yes |
| 2020 | 13 | 2 | Yes |
| 2021 | 13 | 0 | Yes |
| 2022 | 10 | 1 | Yes |
| 2023 | 21 | 0 | Yes |
| 2024 | 16 | 0 | Yes |
| 2025 | 16 | 0 | Yes |
| 2026 | 9 | 0 | No |
110 papers and 6 registered trials between 2017 and 2026. A paper counts when “Gonadorelin” appears in its title or abstract — phrase-matched, so a paper mentioning the words separately is not counted. The total is a single query over the whole window, which is why it does not equal the bars added together: PubMed files a paper under both its electronic and its print publication date, so one paper can appear in two years. Publication volume measures scientific attention, not whether a compound works: a well-studied compound can be well-studied and ineffective. Sources: PubMed and ClinicalTrials.gov · collected 2026-08-02.
Published research on Gonadorelin
110 indexed papers name Gonadorelin in their title or abstract. These are the 8 PubMed ranks most relevant. Listing a paper is not a judgement about it, and none of these is summarised here — follow the link and read what it says.
- Endometriosis
- Menorrhagia
- Endometriosis
- Breast pain
- Premenstrual syndrome
- Breast pain
- Menorrhagia
- Gonadorelin and erythropoiesis
Collected 2026-08-02from PubMed, phrase-matched on “Gonadorelin” in title and abstract. Run the same search.
About Gonadorelin
Synthetic gonadotropin-releasing hormone: the decapeptide pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2, identical in sequence to the hormone released by the hypothalamus. It binds the GnRH receptor on the anterior pituitary. Unlike most entries here it is not an analogue of anything — it is the natural sequence.
- Also known as
- GnRH · LHRH · Luteinizing hormone-releasing hormone
Structure and mechanism only. Nothing above describes what this compound is for, and no dose appears anywhere on this page.
Reading on this compound
All articles →PepRack articles that reference this compound. This is not a news feed — we syndicate nothing and publish no datelines.
Vendor listings are not affiliate links and PepRack earns nothing from them. A listing records a price we observed on a date. It is not a recommendation of a product, dose, or treatment, and PepRack does not verify what any vendor ships.